Month: June 2023

Golar LNG Limited advises that its 2023 Annual General Meeting will be held on August 8, 2023.  The record date for voting at the Annual General Meeting is set to June 15, 2023. The notice, agenda and associated material will be distributed prior to the meeting. Golar LNG LimitedHamilton, BermudaJune 14, 2023 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 19070 DKT 01/09/23 III 3,200 2,200 3,070 100 % 99.347698 19153 DKT 01/12/23 IV 1,680 1,580 3.170 100 % 98.5422Total 4,880 3,780      The sale will settle 16 June 2023.

Philips Neuro suiteJune 14, 2023 Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of a health economic analysis published in the Journal of NeuroInterventional Surgery (JNIS) that show an innovative approach to the stroke care pathway reduced costs by an average of EUR 2,848 (~USD 3,120) per patient. The retrospective analysis looked at data from the controlled single-center ANGIOCAT clinical trial conducted at the Vall d’Hebron University Hospital Stroke Unit (Barcelona, Spain) [1]. Earlier results from this study demonstrated that a ‘Direct-to-Angio Suite’ (DTAS) pathway improves clinical outcomes...

Date: 14 June 2023 Release: Before opening of Euronext Please open the following link to read the full report including annexes:AttachmentFULL PRESS RELEASE

Data shared today on PK/PD and safety from additional KT-333 and KT-413 patient dose escalation cohorts show target knockdown at or near levels associated with clinical efficacy in preclinical tumor models No dose limiting toxicities observed in either program         KT-333 data will be presented in a poster session at the International Conference on Malignant Lymphoma (ICML) on June 16 WATERTOWN, Mass., June 14, 2023 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today shared new data demonstrating that its oncology programs KT-333 and KT-413 continue to demonstrate robust dose-dependent target knockdown in ongoing Phase 1a dose escalation clinical trials, with no dose...